All In Biotech

Drug Trial Radar · NCT07036029

NAL ER IPF Respiratory Function and Safety Study

An Open Label, In-Clinic Study to Assess Respiratory Function and Safety of Escalating Doses of Nalbuphine Extended-Release Tablets (NAL ER) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Aug 21, 2025

Primary completion

Jun 30, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Trevi TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • NAL ERDrug

    Oral tablets

  • PlaceboDrug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Respiratory Function and Safety Assessed by Number of Participants With Increase in End Tidal Partial Pressure of Carbon Dioxide by Capnography (PetCO2) of at Least 10 Millimetres of Mercury (mmHg) From Baseline, or PetCO2>55 mmHg, for at Least 1 MinuteTime frame: Up to Day 6
  2. Respiratory Function and Safety as Assessed by Number of Participants With a Decrease in Blood Oxygen Saturation (SpO2) to <88% for at Least 1 MinuteTime frame: Up to Day 6
  3. Respiratory Function and Safety as Assessed by Number of Participants With a Decrease in Respiratory Rate (RR) to <6 Breaths per MinuteTime frame: Up to Day 6
  4. Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 51

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

  • Medicines Evaluation Unit Ltd.

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.